These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 34559572)

  • 1. Characterizing Out-of-Pocket Payments and Financial Assistance for Patients Prescribed Abiraterone and Enzalutamide at an Academic Cancer Center Specialty Pharmacy.
    Chehrazi-Raffle A; Dorff TB
    JCO Oncol Pract; 2022 Feb; 18(2):97-98. PubMed ID: 34559572
    [No Abstract]   [Full Text] [Related]  

  • 2. Characterizing Out-of-Pocket Payments and Financial Assistance for Patients Prescribed Abiraterone and Enzalutamide at an Academic Cancer Center Specialty Pharmacy.
    Jeong AY; Schwartz EB; Roman AR; McDevitt RL; Oerline MK; Henry E; Veenstra CM; Caram MEV
    JCO Oncol Pract; 2022 Feb; 18(2):e284-e292. PubMed ID: 34491783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adherence and out-of-pocket costs among Medicare beneficiaries who are prescribed oral targeted therapies for advanced prostate cancer.
    Caram MEV; Oerline MK; Dusetzina S; Herrel LA; Modi PK; Kaufman SR; Skolarus TA; Hollenbeck BK; Shahinian V
    Cancer; 2020 Dec; 126(23):5050-5059. PubMed ID: 32926427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Promotional Payments Made to Urologists by the Pharmaceutical Industry and Prescribing Patterns for Targeted Therapies.
    Hollenbeck BK; Oerline M; Kaufman SR; Caram MEV; Dusetzina SB; Ryan AM; Shahinian VB
    Urology; 2021 Feb; 148():134-140. PubMed ID: 33075381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physician Dispensing Among Urology Practices and the Use of Abiraterone or Enzalutamide for Men With Advanced Prostate Cancer.
    Lai LY; Kaufman SR; Oerline MK; Caram MEV; Maganty A; Hollenbeck BK; Shahinian VB
    JNCI Cancer Spectr; 2022 Mar; 6(2):. PubMed ID: 35603854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Promotional Payments to Medical Oncologists and Urologists and Prescriptions for Abiraterone and Enzalutamide.
    Lai LY; Oerline MK; Kaufman SR; Herrel LA; Skolarus TA; Dusetzina SB; Ellimoottil C; Shahinian VB; Hollenbeck BK; Caram MEV
    Urology; 2022 Mar; 161():50-58. PubMed ID: 34861316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The lack of a relationship between physician payments from drug manufacturers and Medicare claims for abiraterone and enzalutamide.
    Bandari J; Ayyash OM; Turner RM; Jacobs BL; Davies BJ
    Cancer; 2017 Nov; 123(22):4356-4362. PubMed ID: 28749536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease.
    Suzuki H; Castellano D; de Bono J; Sternberg CN; Fizazi K; Tombal B; Wülfing C; Foster MC; Ozatilgan A; Geffriaud-Ricouard C; de Wit R
    Jpn J Clin Oncol; 2021 Aug; 51(8):1287-1297. PubMed ID: 33738495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone.
    Ramaswamy K; Lechpammer S; Mardekian J; Huang A; Schultz NM; Sandin R; Wang L; Baser O; George DJ
    Adv Ther; 2020 May; 37(5):2083-2097. PubMed ID: 32112280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of prostate cancer by targeting 3βHSD1 after enzalutamide and abiraterone treatment.
    Mei Z; Yang T; Liu Y; Gao Y; Hou Z; Zhuang Q; He D; Zhang X; Tan Q; Zhu X; Qin Y; Chen X; Xu C; Bian C; Wang X; Wang C; Wu D; Huang S; Li Z
    Cell Rep Med; 2022 May; 3(5):100608. PubMed ID: 35584629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study.
    Sternberg CN; Castellano D; de Bono J; Fizazi K; Tombal B; Wülfing C; Kramer G; Eymard JC; Bamias A; Carles J; Iacovelli R; Melichar B; Sverrisdóttir Á; Theodore C; Feyerabend S; Helissey C; Poole EM; Ozatilgan A; Geffriaud-Ricouard C; de Wit R
    Eur Urol; 2021 Oct; 80(4):497-506. PubMed ID: 34274136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic Review of Efficacy and Health Economic Implications of Real-world Treatment Sequencing in Prostate Cancer: Where Do the Newer Agents Enzalutamide and Abiraterone Fit in?
    Pereira-Salgado A; Kwan EM; Tran B; Gibbs P; De Bono J; IJzerman M
    Eur Urol Focus; 2021 Jul; 7(4):752-763. PubMed ID: 32273196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk for stroke and myocardial infarction with abiraterone versus enzalutamide in metastatic prostate cancer patients.
    Kulkarni AA; Rubin N; Tholkes A; Shah S; Ryan CJ; Lutsey PL; Prizment A; Rao A
    ESMO Open; 2021 Oct; 6(5):100261. PubMed ID: 34509804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Chemotherapy, Enzalutamide, Abiraterone, and Radium 223 With Cognitive Function in Older Men With Metastatic Castration-Resistant Prostate Cancer.
    Alibhai SMH; Breunis H; Feng G; Timilshina N; Hansen A; Warde P; Gregg R; Joshua A; Fleshner N; Tomlinson G; Emmenegger U
    JAMA Netw Open; 2021 Jul; 4(7):e2114694. PubMed ID: 34213559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone.
    Bianchini D; Lorente D; Rodriguez-Vida A; Omlin A; Pezaro C; Ferraldeschi R; Zivi A; Attard G; Chowdhury S; de Bono JS
    Eur J Cancer; 2014 Jan; 50(1):78-84. PubMed ID: 24074764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immediate Prostate-specific Antigen Decline After Enzalutamide Following Abiraterone Predicts Survival in Castration-resistant Disease.
    Fujimoto N; Minato A; Igawa T; Hiroshige T; Obara W; Fukuda A; Nagata Y; Mizushima Y; Tomisaki I; Harada K
    Anticancer Res; 2022 Jun; 42(6):3041-3047. PubMed ID: 35641266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abiraterone and enzalutamide had different adverse effects on the cardiovascular system: a systematic review with pairwise and network meta-analyses.
    Lee HY; Chen HL; Teoh JY; Chen TC; Hao SY; Tsai HY; Huang WH; Juan YS; Cheng HM; Chang HM
    Prostate Cancer Prostatic Dis; 2021 Mar; 24(1):244-252. PubMed ID: 32860011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide.
    Brown LC; Halabi S; Schonhoft JD; Yang Q; Luo J; Nanus DM; Giannakakou P; Szmulewitz RZ; Danila DC; Barnett ES; Carbone EA; Zhao JL; Healy P; Anand M; Gill A; Jendrisak A; Berry WR; Gupta S; Gregory SG; Wenstrup R; Antonarakis ES; George DJ; Scher HI; Armstrong AJ
    Clin Cancer Res; 2021 Jul; 27(14):4077-4088. PubMed ID: 33820782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic role of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with metastatic castration resistant prostate cancer treated with abiraterone or enzalutamide.
    Sciarra A; Gentilucci A; Cattarino S; Salsiccia S; Mariotti G
    Minerva Urol Nephrol; 2021 Dec; 73(6):863-865. PubMed ID: 35144373
    [No Abstract]   [Full Text] [Related]  

  • 20. HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies.
    Khalaf DJ; Aragón IM; Annala M; Lozano R; Taavitsainen S; Lorente D; Finch DL; Romero-Laorden N; Vergidis J; Cendón Y; Oja C; Pacheco MI; Zulfiqar M; ; Gleave ME; Wyatt AW; Olmos D; Chi KN; Castro E
    Ann Oncol; 2020 Sep; 31(9):1186-1197. PubMed ID: 32574722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.